Navigation Links
Interleukin Genetics and NYU Langone Medical Center Announce Publication of Study on Genetics of Osteoarthritis
Date:12/2/2009

next 50 years. OA is caused by the breakdown of the cartilage cushion in one or more joints of the body leading to pain, limitation in movement, and in many cases joint replacement. Therapy for OA patients involves mostly pain management, and no drugs are currently available to limit the progression of the disease.

"Many trials for osteoarthritis therapies have failed due to the inability to identify the group at highest risk for progression over short periods of time," said Virginia Byers Kraus, MD, PhD, collaborator at Duke University. "The identification of these variations in the IL-1 receptor antagonist gene may form one strategy of identifying such individuals that could help release this major roadblock to developing more effective drugs for osteoarthritis."

Interleukin Genetics identified and holds patents on genetic patterns that lead to over-production of interleukin-1, one of the key chemicals involved in cartilage and bone destruction, and on specific genetic patterns that are predictive of OA progression.

"We're excited at the potential for clinical use of our genetic biomarkers to aid drug companies in the development of a treatment to halt the progression of this crippling disease," said Ken Kornman, PhD, Chief Scientific Officer, Interleukin Genetics, Inc. "This publication is the positive culmination of Interleukin Genetics' research on genetic patterns related to interleukin-1 and dedication by our university partners to better understand and treat this disease."

About the Study

The lack of biomarkers that identify patients at risk for severe OA complicates development of disease modifying OA drugs. This study determined whether inflammatory genetic markers could stratify knee OA patients into high and low risk categories for destructive disease.

Genotype associations with knee OA severity were assessed in two independent Caucasian populations, including one population fr
'/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
2. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
6. Interleukin Genetics Wins International Award for Outstanding Research Published in the Journal, Nutrition
7. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
8. Interleukin Genetics and Geisinger to Collaborate on Genetic Tests to Predict Weight Loss Success
9. Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis
10. Interleukin Genetics, Inc. Announces Positive Results from Clinical Study Evaluating Genetic Tests Impact on Weight Loss
11. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... SAN DIEGO , Nov. 18, 2014 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that it filed an Investigational New Drug ... Administration (FDA) on Friday, November 14, 2014.  ... development of a patented formulation of the currently ...
(Date:11/18/2014)...   Rio Grande Valley Health Information Exchange (RGV ... Health Science Center at Houston (UTHealth)  School of Public ... selected Wellcentive,s suite of population health management solutions and ... to partner with hospitals and clinics in the region ... uninsured patient populations, initially focusing on the care of ...
(Date:11/18/2014)... , Nov. 17, 2014   Headquartered ... Inc. (OTC: GWPC) is a diversified company.  WholeHEALTH ... convenience of advanced technology and proven expertise of ... business of health and wellness.  WholeHEALTH Products, comprehensive ... doctors, clinics and healthcare centers, and 8 retail ...
Breaking Medicine Technology:HedgePath Pharmaceuticals Files IND Application 2HedgePath Pharmaceuticals Files IND Application 3HedgePath Pharmaceuticals Files IND Application 4Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 2Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 3Rio Grande Valley Health Information Exchange and University of Texas Health Science Center Select Wellcentive to Manage Health and Cost of Medicaid and Uninsured Populations 4WholeHEALTH Product Inc. to File FDA Emergency Use Approval (EUA) for PCR Rapid Ebola Test 2
... , , LANSING, Mich., Dec. 1 Neogen ... acquired the BioKits food safety business of San Diego, Calif.-based ... test kits for food allergens, meat and fish speciation, and ... acquisition of Tepnel Life Sciences plc in April 2009. Gen-Probe ...
... 1 CEL-SCI Corporation (NYSE Amex: CVM ), a ... for the prevention and treatment of infectious diseases, announced today ... Research Organization (CRO) to run CEL-SCI,s upcoming Phase III clinical ... Company,s lead product candidate, Multikine®. This CRO is considered ...
Cached Medicine Technology:Neogen Acquires Gen-Probe's BioKits Food Safety Business 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 2CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine 3
(Date:11/18/2014)... Cristcot Inc., a global life ... of specialized drug delivery systems, today announced that ... patent for the technology, which encompasses the company’s ... The patent was awarded to the inventor Jennifer ... assigned to Cristcot Inc. The patented technology, titled ...
(Date:11/18/2014)... Steven Reinberg HealthDay Reporter ... with the abnormal heartbeat known as atrial fibrillation who ... bleeding and blood clots, according to a new study. ... took a blood thinner along with one of these ... (Motrin), naproxen (Aleve) and celecoxib (Celebrex). "If ...
(Date:11/18/2014)... Recently, BellasDress has announced the launch of ... workers and using comfortable fabrics, the new styles of prom ... variety of wonderful holiday gifts in a variety of colors ... prom dresses, and they are created by top designers,” said ... absolutely great addition to our sales team and more than ...
(Date:11/18/2014)... Sometimes at inopportune times during hectic ... like unforeseen error messages or paper jams. This ... find another printer and they don’t know who is ... likely tied up with other mission-critical projects in their ... Electronic Systems, Inc. (ESI) comes in. Since ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. ... a severe abusive head trauma before the age of 5 ... study. In addition, among those who survive severe ... study found. Abusive head trauma includes shaken baby syndrome, ... head injuries, according to background information in the study. ...
Breaking Medicine News(10 mins):Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Some Painkillers Tied to Bleeding Risk in Those With Abnormal Heartbeat 2Health News:85 New Models Of White Prom Dresses From BellasDress.com Online For Sale 2Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4
... Nov. 1 Perrigo Company,(Nasdaq: PRGO ; ... Perrigo,s partner for store brand OTC 20mg Omeprazole ... AstraZeneca (the,manufacturer of Prilosec OTC(R)) involving three Orange ... product. While terms and conditions of the,agreement have ...
... Nov. 1 MannKind Corporation,(Nasdaq: MNKD ), focused on ... that it will present at,the following conferences: * The ... Tuesday November 6, 2007 at 2:20 PM ... New York, NY., * The CIBC 18th Annual ...
... American Diabetes Month, HARRISBURG, Pa., Nov. 1 ... Health Dr. Calvin Johnson today urged,Pennsylvanians to adopt healthy ... diabetes., Diabetes is a chronic disease that affects ... in Pennsylvania., "Diabetes is a serious, public health ...
... Statement by James Wagoner on the $28 ... Nov. 1 The following is a,statement ... increase in abstinence-only,program funding:, Today, we ... committee report includes the full $28 million,increase ...
... InfoLogix, Inc. (Nasdaq:,IFLG), a leading technology provider ... industries, will release its financial results,for the Third ... 8th,2007. Following the press release, President and Chief ... Roberts will host a conference,call with the financial ...
... Edwards Lifesciences,Corporation (NYSE: EW ), a ... cardiovascular disease, is scheduled to participate in the,Southern ... Newport,Beach, California on Wednesday, November 7, 2007. ... Investor,Relations, is scheduled to speak to conference attendees ...
Cached Medicine News:Health News:Perrigo Announces that Dexcel's Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval 2Health News:Perrigo Announces that Dexcel's Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval 3Health News:Health Secretary Promotes Awareness of Diabetes, Urges Healthy Habits 2Health News:Democrats Cave on Sex Education - Again 2Health News:InfoLogix to Report Third Quarter and Nine Month Financial Results on November 8, 2007 2Health News:Edwards Lifesciences to Present at the Southern California Investor Conference 2
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Ties improve torso fit and transfer weight to waist and hips. Ties are 1"W cotton woven for flexibility and sewn at an angle across the full width of the two back sections for durability....
Ties improve torso fit and transfer weight to waist and hips. Ties are 1"W cotton woven for flexibility and sewn at an angle across the full width of the two back sections for durability....
Hip-hugging design transfers weight from shoulders to the hips. Crisscross shoulder design provides snug and comfortable upper torso fit while preventing apron from slipping off shoulders....
Medicine Products: